New imaging technique to improve treatment for liver cancer
Official title: Novel PET Imaging to Guide Therapy in Hepatocellular Carcinoma
Funded at University of Tx Md Anderson Can Ctr · NIH-10980028 · Data updated 2026-11-12
This study is testing a new imaging method to help doctors see how well treatments are working for patients with liver cancer, so they can make faster and better decisions about their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $678,515 |
| NIH project number | 1R01CA279467-01A1 |
| Project ID | NIH-10980028 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma who are undergoing locoregional therapies.
✕Less likely to help
Patients with liver cancer who are not eligible for locoregional therapies or those with other types of cancer may not benefit from this research.
What this research studies
This research focuses on developing a novel PET imaging method to better predict how patients with hepatocellular carcinoma (HCC) respond to locoregional therapies like Yttrium-90 radioembolization. By using advanced imaging technology, the goal is to provide quicker and more accurate assessments of treatment effectiveness compared to traditional imaging methods. This could significantly reduce the waiting time for patients and help guide their ongoing treatment decisions. The study aims to evaluate the effectiveness of this imaging approach in detecting cancer cell activity and response to therapy.
Why it matters
Potential benefit: If successful, this research could lead to faster and more reliable treatment decisions for patients with liver cancer.
How similar studies have gone: Previous research has shown promising results with similar imaging techniques in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Manning, Henry Charles — University of Tx Md Anderson Can Ctr
- Study coordinator: Manning, Henry Charles
Related research
Other NIH-funded projects on the same topics.
-
Glutamine and macrophage behavior in liver cancer
A funded project at a medical university aims to understand how the liver’s immune cells interact with a specific type of liver cancer by looking at metabolism, especially glutamine and ammonia.
-
Adding PSMA PET/CT imaging to liver cancer care for veterans
This project tests a new PET imaging approach to help diagnose and guide treatment for liver cancer in veterans.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
Towards a blood-based test using nanophotonic exosomes to screen and diagnose liver cancer
A new blood test using tiny particles shed by liver cancer cells aims to screen for hepatocellular carcinoma earlier and more accurately.
-
Metabolic imaging to guide targeted therapy for liver cancer
A clinician-scientist at UPenn is pursuing training to use metabolic imaging to tailor therapy for hepatocellular carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.